The world is now approaching 20 years since biosimilar medicines were first developed and introduced. Yet, their promise in contributing to access and affordability remains largely unrealized throughout much of the globe. Connecting the dots between availability, affordability, and access has proven difficult, considering increasingly constrained health budgets where biosimilars would still represent a significant cost. This panel will focus on potential methods of enhancing access to essential biosimilar medicines. Specific examples from countries will be raised to discuss challenges in selection and procurement to bridge regulatory approval and post-market access.

Session Material:

⬇️ PS4_session_slides_combined

⬇️ PS4_questions_answers_and_links